In today’s briefing:
- Celltrion Siblings Announced Dividends: Trading Based on Past Patterns
- AstraZeneca ADR: Initiation of Coverage – Recent Approvals & Other Drivers
- Illumina Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
- Illumina Inc.: Initiation of Coverage – New Launches & Other Drivers
Celltrion Siblings Announced Dividends: Trading Based on Past Patterns
- The three Celltrion companies are showing the same pattern of boosting share prices towards the yearend T-1 ex-date. This isn’t unique to Celltrion, but the intensity is high for them.
- Celltrion’s yearend dividend effect has an inverse correlation with the market’s overall performance. Fortunately, this year’s market-wide performance was the worst in the past five years.
- For this year, the dividend yield isn’t bad either, swing on Dec 17 to T-1 ex-date or day trade on T-1 ex-date should provide juicy returns based on past patterns.
AstraZeneca ADR: Initiation of Coverage – Recent Approvals & Other Drivers
- This is our first report on global pharma major, AstraZeneca.
- The company delivered an outstanding set of results, with revenues of nearly $11 billion surpassing Wall Street expectations.
- Overall, AstraZeneca is well-positioned to gain significant revenue in the coming quarters.
Illumina Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
- Illumina is a major provider of sequencing and array-based solutions for genetic and genomic analysis.
- Driven by genetic disease testing and oncology testing, there has been a constant increase in clinical sequencing consumable shipments for the company.
- The company has recently announced an innovative research test for identifying AMR (Antimicrobial Resistance) and genitourinary pathogen infection.
Illumina Inc.: Initiation of Coverage – New Launches & Other Drivers
- This is our first report on Illumina, a well-known provider of sequencing and array-based solutions for genetic and genomic analysis.
- In the quarter, Illumina saw fantastic customer response to the recently launched NovaSeq X Series.
- Driven by genetic disease testing and oncology testing, there was an increase in clinical sequencing consumable shipments.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
